Acadia Pharmaceuticals
ACAD
ACAD
295 hedge funds and large institutions have $2.99B invested in Acadia Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 70 funds opening new positions, 109 increasing their positions, 74 reducing their positions, and 29 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
24% more capital invested
Capital invested by funds: $2.4B → $2.99B (+$584M)
15% more funds holding
Funds holding: 256 → 295 (+39)
3.66% more ownership
Funds ownership: 94.25% → 97.91% (+3.7%)
Holders
295
Holding in Top 10
5
Calls
$18.4M
Puts
$7.74M
Top Buyers
| 1 | +$90.7M | |
| 2 | +$36M | |
| 3 | +$31.7M | |
| 4 |
Citigroup
New York
|
+$25M |
| 5 |
Goldman Sachs
New York
|
+$18.1M |
Top Sellers
| 1 | -$80.7M | |
| 2 | -$23.4M | |
| 3 | -$15.1M | |
| 4 |
FC
Finepoint Capital
Boston,
Massachusetts
|
-$13.9M |
| 5 |
O
OrbiMed
New York
|
-$11.8M |